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A2780 cisplatin sensitive ovarian cancer cell line
A2780cisR cisplatin resistant ovarian cancer cell line
A549 lung adenocarcinoma cells
Ar aryl
BALC/c albino, laboratory-bred strain of the house mouse
Bipy 2, 20-bipyridine
BODIPY 4,4-difluoro-bora-3a,4a-diaza-s-indacene
BT474 human breast carcinoma cells
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C20orf97 chromosome 20 open reading frame 97
Caco-2/TC7 colon cancer cells
CCRF-CEM acute human lymphoblastic leukemia cells
CH1 human ovarian carcinoma cells
c-Myc avian myelocytomatosis virus oncogene cellular homolog
COD 1,5-cyclooctadiene
Cyt cytosine
DAPTA 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane
DCFH-DA dichlorofluorescein diacetate
DNA deoxyribonucleic acid
DPBF 1,3-diphenylisobenzofuran
EC50 concentration of a drug that gives half-maximal response
ERK1 extracellular signal-regulated kinase 1
ERK2 extracellular signal-regulated kinase 2
Et ethyl
Et2bzimpy 2, 6-bis(N-ethylbenzimidazole-2
0-yl)pyridine
Fc ferrocene
FITC fluorescein isothiocyanate
GLUT-1 glucose transporter type 1
GR glutathione reductase
HaCaT immortalized human skin keratinocytes cells
HBL-100 human breast epithelial cells
HCT116 colorectal carcinoma cells
HCT-116-luc human colon cancer cell line luciferase labeled
HEK (HEK293) human embryonic kidney cells
HeLa human cervix cancer cells
Hep3B human hepatocellular carcinoma
HepG2 human liver cancer cells
HL60 promyelocytic leukemia cells
HOMO highest occupied molecular orbital
HPL1D immortalized human lung epithelial cells
HT29 colon carcinoma cells
IAP inhibitor of apoptosis protein
IC50 concentration of an inhibitor where the response (or binding) is reduced
by half
IGROV1 human ovarian carcinomas cells
KB epidermal carcinoma cells
LOVO colon adenocarcinoma cells
LUMO lowest unoccupied molecular orbital
MAPK mitogen activated protein kinases
MCF7 breast adenocarcinoma cells
MDA-MB-231 human breast cancer cells
Me methyl
NCI-H460 human lung carcinoma cells
NCI-H522 lung cancer cells
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
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NHC N-heterocyclic carbene
NIR near-infrared
NSCLC non-small cell lung cancer
PARP poly-ADP(adenosine diphosphate)-Ribose Polymerase
pBR322 plasmid
PC3 prostate adenocarcinoma cells
PCNA proliferating cell nuclear antigen
PDT photodynamic therapy
PEA15 phospho-enriched protein in astrocytes 15 kDa
PEG polyethylene glicol
Ph phenyl
PI propidium iodide
PSs photosensitizers
PTA 1,3,5-triaza-7-phosphaadamantane
RC124 human kidney cells
RIP-1 receptor interacting protein 1
ROS reactive oxygen species
SAR structure-activity relationship
SF-268 human brain carcinoma cells
SKHep-1 human hepatoma cell line
SKOV3 human ovarian carcinoma cells
STK15 centrosome-associated serine/threonine oncogenic kinase
SW480 human ovarian carcinoma cells
Terpy 2,20:60,20 0-terpyridine
TNF tumor necrosis factor
TPPTS triphenylphosphane trisulfonated
TrxR thioredoxin reductase
1. Introduction
The study of transition-metal alkynyl complexes has been a very active
area of research for many years, not only from the organometallic point of
view but also for their use in luminescence, catalysis or material science.1,2
For example, oligomeric or polymeric alkynyl species have particularly prom-
ising electronic and structural properties, which include nonlinear optical
effects,3,4 luminescence,5 electronic communication as molecular wires,2
and liquid crystallinity.6 These properties and relevance of the alkynyl ligands
in supramolecular chemistry are based on three special characteristics: their
linear structure, their high stability, and their π-electron conjugation.
The C^C bond also constitutes a focal point for different reactivity
studies (Fig. 1). The first one is the formation of cluster compounds in which
the alkynyl ligand bridges multiple metal centers,7 providing the final species
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with interesting luminescent properties.8,9 Alkyne derivatives can undergo
several transformations into other interesting species such as vinylidene,
allenylidene, or cummulenylidene, for which several examples with differ-
ent metal centers have been reported.10,11 Additionally, in many organic
transformations the alkyne precursors undergo addition or cyclization reac-
tions in the present of a metal catalyst for which interesting MdC interme-
diates have been proposed.12
Alkynyl ligands can be regarded as isoelectronic with C^N, C^O, and
N2, and can also be comparable to a pseudohalide because of the similar
behavior in complex formation and precipitation reactions. Thus, the chem-
istry of alkynyl transition-metal complexes can be regarded as classical coor-
dination chemistry, albeit being also part of organometallic chemistry.13
Alkynyl ligands can be interpreted as being good σ- and π-donors and poor
π acceptors. This has been corroborated by Extended H€uckel band calcula-
tions and photoelectron spectroscopic measurements, which showed that the
band gap between the HOMO metal d orbitals and the LUMO π* alkynyl
orbitals is too large (ca. 15 eV) for π-accepting behavior, unless strong
π-acceptor substituents in conjugation with the alkynyl unit are present.14
However, in spite of the huge amount of possibilities for alkynyl ligands
in the synthesis of metal complexes and potential applications, it was not
until recently that metal complexes were studied for their biological prop-
erties; specifically for gold and platinum compounds. The medicinal chem-
istry of metallic complexes actually started with the discovery of the high
activity of cis-diaminodicloroplatinum(II) (cisplatin) toward several types
of cancers. Subsequent platinum drugs were approved as chemotherapeutic
agents15 but because of the several drawbacks that the platinum drugs pres-
ented, such as undesired side effects, drug resistance and the narrow effec-
tivity scope toward different tumors, research into other metal complexes as
potential metallodrugs was impulsed.16,17 Gold compounds are among the
most studied metal-based drug for this purpose, and many derivatives have
been reported with antitumor properties.18,19
Stability of the gold derivatives in the biological media is an important
feature for the development of gold-based drugs. For that reason complexes
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Fig. 1 Some binding modes of the alkynyl ligand.
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bearing strong ligand-metal bonds that allowabetter stability against dissociation
in the biological media have been studied. Some examples of these ligands
(Fig. 2) are thiolates,20,21 dithiocarbamates,22,23 thioureas,24 phosphanes,25
phospholes,26 N-heterocyclic carbenes,27 ylides28 or cyclometallated ligands,29
for which many metal complexes have been reported in the last decades with
excellent biological activity.
It is noteworthy that, despite the great stability shown by the metal-
carbon bonds in the alkyne ligands for gold and platinum, it was not until
recently that these complexes were studied for anticancer properties.
Additionally, their high stability to dissociation could exhibit a different
mechanism that those shown by gold or platinum species. In these sense
whereas platinum derivatives have the DNA as the main biological target,
gold presents different pathways for the cytotoxicity, and relevant gold–
protein interactions, mainly those bearing cysteine and/or selenocysteine
moieties, could be the potential biological targets responsible for the
cytotoxic effects of gold compounds.30,31
This review covers the chemistry of gold and platinum complexes bear-
ing alkynyl ligands that present antitumor activity. The type of complexes
which exhibit antiproliferative properties, together with the different studies
performed to elucidate the mechanism of action will be commented.
2. Gold alkynyl derivatives
As has been commented above, organometallic gold complexes,
including N-heterocyclic carbene and cyclometallated species with antip-
roliferative activity have been deeply studied, but in contrast organometallic
Fig. 2 Gold-based complexes with different ligands that exhibit cytotoxic activity.
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complexes with alkynyl ligands are much less represented. Most of the
synthesized complexes are alkynyl or propargyl species bearing different
substituents, and with phosphanes as ancillary ligands. Such complexes tend
to exhibit remarkable stability due to the high bond dissociation energies
around the gold center. Alkynyl ligands are strong σ- and π-donors and
recent studies combining photoelectron spectroscopy and theoretical calcu-
lations found the gold-carbon bond in alkynyl gold complexes to be one of
the strongest gold-ligand bonds known.32 The high stability of these com-
plexes under physiological conditions might overcome one of the main
issues in the development of new metallodrugs: their tendency to decom-
pose before reaching the target due to reaction with biologically occurring
reducing agents such as thiols.
2.1 Alkynyl complexes with triphenylphosphane
as ancillary ligand
The first two examples of alkynyl derivatives with antitumor activity were
described almost simultaneously in 2009. Thus, the two diethynylfluorene
gold(I) complexes with triphenylphosphane (1 and 2) depicted in Fig. 3 have
been studied for their antitumor activity against three human carcinoma cell
lines (Hep3B human hepatocellular carcinoma, SKHep-1 hepatoma and
MDA-MB-231 human breast cancer cells).33 The presence of carbonyl
group in the diethynylfluorene moiety seems to be essential for the antip-
roliferative activity, since no cytotoxicity was observed in the case of com-
plex 1 but better cytotoxicity than that found in cisplatin was exerted by
complex 2. In fact, the latter complex was able to induce intracellular reac-
tive oxygen species (ROS) on Hep3B human hepatocellular carcinoma cells
and reduce the mean tumor volume in treated mice with limited toxicology
effects, as no necrotic features were found in the livers and kidneys examined
after mice autopsy. Phosphane gold(I) propargyl ethers such as 7-chloro-(4-
propargyloxy)quinoline (molecule derived from chloroquine, the most
effective drug for malaria treatment), 1-propargyloxynaphthalene and
2-propargyloxybenzophenone (complexes 3–5, Fig. 3) were found to be
active against ovarian and colon cancer cell lines (chemosensitive ovarian
cancer CH1 and SKOV3, with intrinsic resistance to cisplatin and colon can-
cer cell line SW480).34 Similar IC50 values were shown in both complexes
and consequently none structure-activity relationship can be inferred.
Mononuclear alkynyl triphenylphosphane gold(I) derivatives (6–11,
Fig. 3) with different alkyne ligands have shown strong antiproliferative
activity with IC50 values between 0.8 and 12 μM against MCF7 breast
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adenocarcinoma and HT29 colon carcinoma cells.35 Faster uptake of com-
plexes with smaller alkynyl molecules could be concluded from cellular
uptake studies by measuring the gold content inside HT29 cells by high res-
olution continuum source atomic absorption spectroscopy. These deriva-
tives exhibited strong inhibition of the selenoenzyme thioredoxin
reductase TrxR, besides low inhibition of the related enzyme glutathione
reductase (GR), thus establishing high selectivity to TrxR compared to
GR. These compounds have displayed significant anti-angiogenic effects
in zebrafish embryos in addition to a decrease of tumor cell impedance
Fig. 3 Alkynyl triphenylphosphane gold(I) derivatives.
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and extracellular acidification, which points to mitochondria as a major tar-
get organelle, similarly to other gold metallodrugs.36–41 Complex 6 was
selected for further studies42 that included tumor selectivity and mechanistic
approaches related to protein kinases. Thus, microscopic live cell imaging
revealed morphological changes in RC124 kidney cells during the first
6 h of exposure to complex 6 consistent with the presence of interactions
of the gold compound with components of the cell surface or extracellular
matrix. Incubation of 6with HT29 colon cancer cells led to a significant and
persistent activation of the mitogen activated kinases (MAPK) ERK1 and
ERK2, both involved in growth factor signaling and consequently respon-
sible to regulation of biological functions such as cell growth, differentiation
and survival.
Coordination of the triphenylphosphane gold moiety to propargylic
amine ligands (complexes 12–14, Fig. 3) led to a family of derivatives,43
in which the presence of different substituents on the nitrogen atom mod-
ulates their overall cytotoxic properties. Therefore, the most effective in
inhibiting cell growth in HT29 human colorectal carcinoma, IGROV1
human ovarian carcinoma andHL60 promyelocytic leukemia cell line, were
both complexes 13a and 13d with para-substituted benzene sulfonamide
unit. However, they also showed significant cytotoxicity against non-
malignant human epithelial intestine cell line I407. Complex 13a caused cell
cycle arrest in S phase for HT29 and IGROV1 cells and in the G0/G1 phase
for HL60 with a well detectable fraction of DNA present as a sub-G1 peak,
suggesting DNA fragmentation. These effects have been associated with an
interaction with DNA, supported by the calculation of a dissociation con-
stant of the complex with salmon sperm DNA in the sub-micromolar range.
Conversely to that observed in the rest of the derivatives 12–14, complex
13a did not show any inhibitory effect on the thioredoxin reductase activity.
2.2 Alkynyl complexes with different phosphanes
as ancillary ligands
In order to study the structure-activity relationship in this type of complexes,
a systematic design of an extensive family of gold compounds has been
described.44 Accordingly, the implication of electronic and steric factors
in the antiproliferative activity and the inhibition of the thioredoxin reduc-
tase activity have been evaluated. Thus, the presence of different electron-
donating moieties in para position of phenylacetylene and the use of a series
of phosphanes with different degree of electron-donating properties, mod-
ifying the R group, lead to the preparation of a large number of phosphane
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alkynyl gold(I) derivatives (complexes 15–25a–e, Fig. 4). It was observed
that, in general, compounds with strong electron-donating moieties,
which result in the delocalization of the metal active center, displayed
high inhibition efficacy of TrxR activity, being complex 22c, with
4-methoxyphenylalkyne and thienyldiphenylphosphane as ligands, the most
efficient, with EC50 (half maximal effective enzyme inhibition concentra-
tion) value of 2.8 nM. Moreover, complex 22c was able to inhibit TrxR
through irreversible inactivation of redox-active selenylsulfide motif and
with remarkable specificity, as derived from the low inhibition efficacy of
Fig. 4 Alkynyl derivatives with different phosphane molecules.
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the related enzyme glutathione (GR). The same complexes were able to
reduce TrxR activity and showed high efficiency in the inhibition of cell
proliferation of MCF7 breast adenocarcinoma and HT29 human colorectal
carcinoma. Complex 22c displayed again the highest efficacy, with the low-
est IC50 values (0.03 μM inMCF7 cells and 0.10 μM in HT29 cells) in addi-
tion to other cell lines such as epidermal carcinoma cells (KB), breast cancer
cells (MDA and MB-231), human lung cancer cells (A549) and human
cervical cancer cells (HeLa). Furthermore, 22c displayed much higher cyto-
toxicity to tumor cells than normal cells (human embryonic kidney cells and
immortal hepatic cells) and the ability to reduce tumor volume in in vivo
studies by using MCF7 cells xenografted BALC/c nude mice model.
With the aim to extend the structure-activity relationship to a family of
compounds derived from 4-ethynylanisole, the complexes with different
phosphanes including the water soluble molecules PTA (1,3,5-triaza-7-pho-
sphaadamantane) and DAPTA (3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo
[3.3.1]nonane) (complex 6 and complexes 26–30, Fig. 4) have been
described and screened for their biological properties.42 Complex 26 with
triethylphosphane turned out to be the most active against HT29 colon
carcinoma and MDA-MB-231 breast adenocarcinoma, with the lowest
IC50 values in both cell lines. However the observed values were in a rather
narrow range (1–5 μM) and no conclusions concerning structure-activity
relationship could be established. All the complexes were efficient inhibitors
of thioredoxin reductase with IC50 values in the nanomolar range, with a
linear correlation between the anticancer activity and the inhibition of this
enzyme.
Water soluble alkynyl derivatives with the phosphanes PTA andDAPTA
have been characterized as cytotoxic compounds against the cisplatin
sensitive (A2780) and cisplatin-resistant (A2780cisR) human ovarian cancer
cells (31–34, Fig. 4).45 The IC50 values for complexes 31a and 34b were
similar in both cell lines and of the same order to those found in auranofin,
which suggest these compounds can overcome the resistance to cisplatin
supporting the hypothesis of a different mechanism of action of the gold
derivatives. In fact, no interaction with DNA was detected after their
incubation with the plasmid pBR322 DNA at 37 °C. Thanks to their
luminescent properties, their cellular uptake has been determined by using
epifluorescence microscopy, showing their effective and fast cell internali-
zation. An in-depth analysis to determine the mechanism of action of some
of these alkynyl phosphane derivatives has revealed the significance of the
alkyne structure. Thus, the PTA counterpart 34a to the previously reported
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34b as a cytotoxic complex to ovarian cancer cell lines, has demonstrated to
display strong antiproliferative activity against colon cancer cells46 Caco-2/
TC7, which seemed to be selective to normal enterocytes (Caco-2/TC7
spontaneously differentiate in culture in enterocyte-like cells).47 This
cytotoxicity is due to the inhibition of the enzyme TrxR, which produces
an increase in ROS levels leading to apoptosis induction by dissipation of
mitochondrial membrane potential, release of cytochrome c and indirectly
by altering the balance between pro-apoptotic and anti-apoptotic proteins.
Although the related PTA derivative 35, with 2-ethynylpyridine as alkyne
ligand, displayed a similar IC50 value to that of complex 34a on colorectal
adenocarcinoma Caco-2/TC7 cell line, the introduction of an additional
N atom in the alkyne skeleton lead to different behavior against these
cancerous cells. The main difference came from the abnormal ROS produc-
tion, accompanied of a scarce inhibition of TrxR activity, which triggered
TNF-induced necroptosis dependent of RIP-1 activation and NF-κB
signaling.48 In addition, viability studies of Caco-2 spheroids (3D cell
culture) in the presence of increasing concentration of complex 35 caused
cell death in a tumor-like environment, suggesting the prevalence of anti-
proliferative properties into a living organism.
Lower effects against tumor cell growth (HT29 colon carcinoma and
MDA-MB-231 breast cancer cells) were observed in complexes 36a–b,49
or even no cytotoxicity in the case of 36c50 (with triphenylphosphane
trisulfonated, TPPTS). These three compounds are structurally related to
35, where the position of the nitrogen atom has been changed. However
they displayed different behavior toward cancer cells which reinforces the
relevance of small changes in the complex structure.
A series of S-propargylthiopyridine and thiopyrimidine with gold
complexes bearing the phosphanes PTA and DAPTA (37–40a–b, Fig. 4)
have been reported51,52 as better cytotoxic derivatives than cisplatin against
human colon cancer cell lines Caco-2/PD7 (from early passage) and
Caco-2/TC7 (from late passage). No significant influence of the substituents
of the alkyne moiety has been observed. However, a considerable difference
in the antiproliferative activity was found depending on the phosphane,
being more active complexes with the PTA ligand. Accordingly with these
findings, higher cellular uptake was measured by ICP-MS analysis for the
PTA derivatives, probably due to a worse permeability of the DAPTA
ligand in comparison with PTA. Moderate values of the binding constant
were obtained for the interaction of these compounds with bovine serum
albumin (BSA) and a balanced relationship between lipophilicity and
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hydrophilicity could be inferred from the corresponding partition coeffi-
cient values between water and n-octanol. These results may imply an easy
transport through multiple mixed water-lipid layers with a subsequent
release to the target. Moreover, administration of complex 37a to athymic
nude mice xenografted with human HCT-116-luc cancer cells lead to
an increase in the mean survival time and life expectancy and moderate
inhibition tumor growth without acute toxicity.52
2.3 Polynuclear gold alkynyl derivatives
Heterodinuclear and trinuclear gold(I) and copper(I) alkynyl complexes
(41a–b and 42a–b, Fig. 5)51 derived from 37a–b have remarkably improved
their cytotoxicity compared to their precursors, with the best IC50 value of
0.2 nM for the PTA compound 41a. This is not surprising because other
bimetallic derivatives had shown an improvement in their antitumor activity
in comparison with their mononuclear precursors, including Ti-M
(M¼Au, Ru, Pd, Pt), Au–Ru or Pt–Au combinations.53–58 However com-
plexes 41a–b comprised the first examples of bimetallic Au–Cu species, also
including alkynyl ligands. The interaction of both metals with different
Fig. 5 Polynuclear alkynyl gold(I) complexes.
12 Elena Cerrada et al.
ARTICLE IN PRESS
biological targets seems to be the reason of the improved antiproliferative
effect found in the reported polynuclear compounds.
Bildstein, Ott and coworkers59 have recently reported two
cobalteceniumethynyl gold(I) derivatives (43 and 44, Fig. 5) but only the
monoalkynyl gold complex 43 displayed antitumor effect in HT29 colon
carcinoma and MDA-MB231 breast cancer cell lines, probably because of
its effectivity in inhibiting TrxR activity. However, no selectivity was
observed for the best complex, as its activity in non tumor cell line (RC-
124 human kidney) was similar to that measured in the cancerous cells.
Unexpectedly, the dialkynyl derivative 43was inactive against the cancerous
cells and showed minor effects against the non tumor RC124 cells.
A family of dinuclear diphosphane gold(I) derivatives with 4-
ethynylpyridine60 (45a–d, Fig. 5) has been described as highly cytotoxic
complexes against MCF7 breast cancer and HT29 colon carcinoma cells.
Only complexes with bis(diphenylphosphino)methane (dppm) and 1,4-bis
(diphenylphosphino)butane (dppb) were described as active TrxR inhibi-
tors. The counterpart diphosphanes with cyclohexyl groups led to com-
plexes 45a–b with low solubility in the biological media, which seems
to be in accordance with the missing activity against the enzyme TrxR.
Combination of 1,2-bis(diphenylphosphino)etane (dppe) with a propargyl
amine afforded the dinuclear complex 46 as an effective inhibitor of TrxR.43
High selectivity was found in this case since it showed inactivity against non-
malignant epithelial intestinal cell line I407 and high cytotoxicity toward
HL60 leukemia cell line, although lack of toxicity was found toward
HT29 colon carcinoma cells and IGROV1 human ovarian carcinoma.
2.4 Alkynyl gold derivatives with fluorophore ligands
Fluorescence microscopy cell imaging has been shown as an excellent
tool for visualization of drug cellular uptake and its biodistribution
inside the cell, being possible to distinguish its localization in nucleus or
other organelles within the cytoplasm. This information is relevant for
the elucidation of structure-activity relationship. With this idea several
luminescent alkynyl gold(I) derivatives have been designed with chromo-
phore ligands by Pope and coworkers.61 Thus, the use of mono- and
dipropargylated dihydroxyanthraquinones afforded mono- and dinuclear
alkynyl complexes 47–49 (Fig. 6) that resulted highly cytotoxic against
MCF7 breast adenocarcinoma (IC505 μM), although less effective toward
A549 lung adenocarcinoma, PC3 prostate adenocarcinoma and LOVO
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colon adenocarcinoma. These results are in accordance with the fact that
MCF7 cancer cells have higher mitochondrial mass than many other
immortal cell lines and the mitochondria are believed to be the intracellular
target for most of the gold complexes. Better uptake of the gold complexes
was observed in MCF7 cells in comparison to the free ligands using cellular
Fig. 6 Alkynyl gold derivatives with fluorophore moieties.
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imaging. The metallic derivatives were accumulated in a significant concen-
tration across the entire cytoplasm including the organelles.
Coumarine derivatives were also used as chromophore ligands for deliv-
ering fluorescent cytotoxic species. In particular, a functionalized coumarine
with a propynyloxy group at 4- or 7-position or two propynyloxy groups in
the 6,7-positions, have afforded mono- and dinuclear gold(I) luminescent
derivatives (50–53, Fig. 6)49,50 with the water soluble phosphanes PTA,
DAPTA and TPPTS and the corresponding bis-alkynyl complexes (54 and
55, Fig. 6).49 The anionic compounds 54 and 55 displayed strong cytotoxicity
against HT29 colon carcinoma and MDA-MB-231 breast cancer cells, with
IC50 values ranging from 1.8 to 4.08 μM. This high activity has been attrib-
uted to the cation tetraphenylphosphonium, since the free coumarins were
not cytotoxic and the salt PPh4Cl displayed high antitumor activity. The
neutral phosphane complexes 50–53 exhibited from low to moderate cyto-
toxicities that in the case of 51c and 53a–b were justified by the aggregation
effects detected in aqueous solution that hampered their bioavailability. High
inhibition of the enzyme thioredoxin reductase has been exerted by all the
complexes, being more accentuated for the neutral derivatives.
A series of triphenylphosphane gold(I) derivatives with alkyne ligands
derived from chromone (complexes 56a–b, Fig. 6)62 and flavone (com-
plexes 57–58, Fig. 6)62,63 molecules have been described and biologically
examined. Both chromones and flavones are plant metabolites of recog-
nized medicinal importance and some examples of their metallic deriva-
tives have been shown anticancer and antibacterial activity in addition
to be employed as luminescent probes in bioimaging.64 The corresponding
alkynyl chromone gold(I) 56a–b and the alkynyl flavone gold 57 deriva-
tives exhibited similar antiproliferative effects than that of auronafin against
HepG2 hepatocellular carcinoma, MCF-7 estrogen-responsive breast can-
cer cells, MDA-MB-231 estrogen-unresponsive breast cancer cells and
CCRF-CEM hematological T-lymphoblast-like cancer cells via TrxR inhi-
bition, caspase-9 and caspase-3 activations, cell cycle disturbance and DNA
damaging activity. Flavonoids complexes 55a and 55b improved the cyto-
toxic effects on PC-3 human prostate cancer cells in comparison to the
flavones and the propargyl ether flavone precursors. However, onlymoderate
IC50 values were obtained and similar to those found with the precursor
[AuCl(PPh3)].
63
Functionalization of 1,8-naphthalimide chromophores in 4-position and
posterior coordination to the AuPPh3 moiety via a terminal propargyl donor
provided a family of luminescent gold(I) derivatives (59a–g, Fig. 6).65
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The evaluation of their antiproliferative effects on several cancerous cells
(MCF7 breast adenocarcinoma, A549 lung adenocarcinoma, PC3 prostate
adenocarcinoma, LOVO colon adenocarcinoma) and HEK (human embry-
onic kidney) cell line established that all derivatives were more toxic to HEK
cells than to the cancer cell lines. However, the most active ones against can-
cer cells were complexes displaying the glycol appended substituent amine
59b and 59c (IC50 values ranging from 5.1 to 51.9 μM). Uptake studies into
HEK cells and the protistan fish parasite Spironucleus vortens by confocal
fluorescence microscopy showed propensity for the localization of the
most liphophilic derivatives in mitochondria (in HEK cells) and in hydro-
genosomes in Spironucleus vortens.
Heterometallic AudRe complexes have been described as excellent part-
ners in cell imaging and cancer therapy.66 Thus, the luminescent rhenium
derivative fac-[Re(bipy)(CO)3L]
+ with L alkynyl-imidazole or alkynyl-
pyridine afforded dinuclear complexes 60a–c (Fig. 6) after coordination of
the AuPPh3 unit to the alkyne. Higher cytotoxicity was exerted by the
heterometallic derivatives toward A549 lung carcinoma cells, in comparison
with the mononuclear rhenium precursors (IC50 values >10 times lower).
Confocal fluorescent images revealed a concentration dependent localization
pattern, since incubation of cancer cells with the complexes at concentration
below their IC50 values showed a similar pattern to that of monometallic
species, concordant with cytoplasm localization. However, higher loading
concentration up to 150 μM prompted higher complex internalization than
the monometallic analogs leading to accumulation in a specific organelle in
the nucleus.
2.5 Alkynyl carbene gold derivatives
Although N-heterocyclic carbene derivatives have been widely studied as
anticancer agents,40,67–70 only one example of mixed NHC-alkynyl com-
plex (61, Fig. 7) with antiproliferative activity has been described so far.71
Complex 61 displayed similar activity than cisplatin toward the two different
cancer cell lines HCT116 colorectal carcinoma (p53 wild-type and p53 null
variant), MCF7 breast adenocarcinoma and A375 malignant melanoma.
The lack of selectivity observed for both HCT116 cell lines points to a
mechanism independent of p53 activity. Complex 61 evidenced low toxic-
ity in an ex vivo model in healthy rat tissue using the PCKS technology.
Thus, a TC50 (toxic concentration) value greater than 50 μMwas measured
for the mixed carbene-alkynyl derivative after its incubation with kidney
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slices, conversely to the observed for cisplatin and auranofin. Moreover,
non-significant morphological changes relative to controls were detected
in the treated organs.
3. Platinum alkynyl derivatives
Cisplatin is the main metal-based drug used in cancer therapy.72 Its
effectiveness has been proven in a great variety of tumors including ovarian,
testicular, head and neck, breast, prostate and lung cancer, which boosted the
development of a second generation of platinum drugs.73 However, the vast
amount of work was devoted to the development of analogous species that
mimic the coordination nature of the cisplatin, leaving organometallic com-
plexes relegated to a second position.74 Alternatively, organometallic platinum
complexes and in particular alkynyl derivatives have lately demonstrated their
capacity as anticancer agents, with excellent IC50 values and in some cases
exceeding that of cisplatin.
3.1 Glycosylated alkynyl platinum complexes
with terpyridine ligands
Glycosylated alkynyl platinum derivatives bearing terpyridine ligands were the
first examples reported in the literature where the antitumoral activity of an
akynyl platinum complex was tested. Che and coworkers pioneered
this investigation in 2005 with the development of a series of terpyridine plat-
inum complexes containing either glycosylated alkynyl (complexes 62–64),
glycosylated arylalkynyl (complexes 65–68) or arylalkynyl (69) as ancillary
ligands (see Fig. 8).75 These systems were appealing due to different factors,
(a) they would be able to act as metallointercalators for biomolecules,
(b) the strength of the PtdC bond would avoid hydrolysis problems seen
for [Pt(terpy)Cl]+ and, (c) the solvent media dependence of the photo-
luminescence properties of [Pt(terpy)(C^CdAr)]+ and related compounds
Fig. 7 Mixed NHC-alkynyl derivative.
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could be used for signaling studies of biological interest. Additionally, they
suggested that introduction of a glucopyranoside group would promote water
solubility as well as specificity toward glycosylated biomolecules. Thus, after
analyzing thebehavior of these complexes by electrophoresis andUV spectros-
copy, it could be concluded that both families, the glycosylated alkynyl and the
arylalkynyl derivatives bind to DNA. However, only the arylalkynyl deriva-
tives 65–67 were emissive in aqueous solution indicating that the presence
of the aryl moiety was crucial for reaching the emissive behavior. All of them
showed high antiproliferative activity against five human carcinoma cell lines
(HeLa (cervix), HepG2 (liver), SF-268 (brain), NCI-H460 (lung), MCF-7
(breast)), being those of the glycosylated arylalkynyl derivatives (65–68) the
most toxic species (IC50¼0.06–0.2 μM), around 100 times more cytotoxic
than the cisplatin in the same conditions. This study also revealed the impor-
tance of avoiding acetylated imine moieties, as complexes 62 and 63were the
less active complexes within the five cell lines, with IC50 values ranging from
15 to 28 μM.Additionally, the glycosylated arylalkynyl system seems to govern
the cell death pathway, which was mainly due to an apoptotic process. It was
found that 67 significantly regulated several genes such as C20orf97, PEA15,
STK15 and PCNA with roles in cell proliferation and apoptosis, whereas the
68 (lacking of glycosylate pyranosyl) as well as the parent complex [Pt(terpy)
Cl]+ did not show any regulation.
3.2 Alkynyl platinum complexes with COD ligands
Alkynyl platinum complexes containing 1,5-cyclooctadiene (COD) ligand
instead of terpyridine backbone were investigated as antitumoral agents by
Fig. 8 Terpyridine platinum complexes containing glycosylated acetylide ligands.
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A. Klein and coworkers in 2010.76 Some years earlier it was demonstrated that
complexes following the general formula [Pt(COD)(Me)(Nuc)]NO3 (Nuc:
guanosine, cytosine or adenosine nucleosides) retained its preferential binding
to guanosine, as themajority of platinum complexes. Additionally, similar spe-
cies such as [Pt(COD)(Me)(Cl)] and [Pt(COD)(Me)(Cyt)](SbF6) exhibited
also high toxicity in colon HT-29 and breast MCF-7 carcinoma cells.77
Therefore, they intended to elucidate whether the introduction of various
electron rich coligands to the platinum COD core could improve the cyto-
toxic potential. Hence, a series of neutral platinum complexes [Pt(COD)(Me)
(C^CdR)] (Fig. 9), with R¼4-fluorophenyl (70), 4-tolyl (71),
4-nitrophenyl (72) or phenyl (73), were synthesized and their cytotoxic activ-
ity analyzed in two different cell lines, colon carcinoma HT-29 and MCF-7
breast adenocarcinoma cells.76 The IC50 values found ranged from 0.2 to
10 μM, being 71 the most cytotoxic species. However, no specific antip-
roliferative trend was observed. Several years later, a second attempt was made
using the same type of COD-Pt core. This time, mono- and dialkynyl
platinum-COD derivatives, complexes 74–89, were synthesized and their
antiproliferative activity analyzed (Fig. 9), which led to some interesting con-
clusions regarding the structure-activity relationship (SAR).78 In general, the
dialkynyl platinum complexes were more cytotoxic than the corresponding
methyl substituted ones. The IC50 values were below 0.6 μM in every case.
It seemed clear that quicker decomposition of the Pt-alkynyl bond, provides
better antiproliferative activity. Moreover, the perpendicular orientation of
the C^C-aryl group to the Pt coordination plane might be also affecting
the cytotoxic character. Furthermore, the different methyl substitution on
the aromatic ring (orto (82), meta (83), para (84)) barely affected the antip-
roliferative behavior. Alternatively, differences were found in the case of
the nitro group, being the orto substituted (85) the less active species. Finally
these complexes showed inhibition of the enzyme thioredoxin reductase
(TrxR), which in addition to DNA, could be also a potential biological target.
Fig. 9 Alkynyl platinum complexes containing COD.
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3.3 Alkynyl platinum complexes with planar
polyaromatic ligands
Cyclometalated platinum alkynyl complexes containing tridentate C^N^N
ligands (Fig. 10), were investigated by Chen, Huo and coworkers.79 Organ-
ometallic platinum species containing either tridentate C^N^NorN^C^N
coordinating ligands have been far less investigated, possibly because the
focus has been always on cisplatin analogs as previously commented.80
However, these types of scaffolds when incorporated to platinum metal
were found to afford anticancer activity by inhibiting the expression of sur-
vivin (a novel inhibitor of apoptosis protein, IAP), activating poly(ADP-
ribose)polymerase (PARP) and inducing apoptosis.81 Moreover, in general
they have rich photophysical properties that allows the use of fluorescence
techniques, for assessing their biodistribution.82 Consequently, they are
potential candidates for novel trackable anticancer agents. Examination of
different C^N^N-ortometallated platinum complexes containing alkynyl
(90 and 91) or chloride (90a and 91a) units as ancillary ligands revealed that
the presence of the labile chloride was critical.79 None of the alkynyl deriv-
atives (90 and 91) showed significant cytotoxicity in lung cancer NCI-H522
Fig. 10 Tridentate C^N^N, Terpy and Et2bzimpy alkynyl platinum(II) complexes.
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cells (IC50>162 μM for both of them). It can be then hypothesized that for
this type of species, dissociation of PtdCl bond may be indispensable for
cytotoxicity.
Additionally, platinum(II) complexes containingplanar polyaromatic ligands
have shown to be selective G-quadruplex binders.83,84 G-quadruplexes are
involved in the regulation of telomerase activity, a ribonucleoprotein that is
activated in 80–90% of human tumors and can serve as specific tumor-selective
targets for chemotherapy.85 Therefore developing good G-quadruplex stabi-
lizers may show antitumor effects against a wide range of cancer cells. The judi-
cious choice of auxiliary ligands as well as increasing the π surface on the
complexes leads to an increase inbinding affinity and selectivity forGquadruplex
over duplex DNA.86 Gao and coworkers have explored such possibility with
alkynylplatinum derivatives containing either 4-(4-methylphenyl)-2,20:60,200-
terpyridine (terpy) (92–94, Fig. 10)87,88 or 2, 6-bis(N-ethylbenzimidazole-20-
yl)pyridine (Et2bzimpy), (95–97, Fig. 10) as the polydentate ligand.
89 The
σ-alkynyl ancillary ligands chosen were either pargyline, peralkylated ammo-
nium derivatives or erlotinib, which is a first-line treatment in patients with
non-small cell lung cancer (NSCLC). Analysis of the cytotoxic activity in
lung adenocarcinomaA549 cells revealed that terpy derivativesweremore cyto-
toxic (IC50 ca. 1 μM) than the Et2bzimpy analogous (IC50 ca. 8 μM).Regarding
the alkynyl ligand, the quaternary ammonium alkynyl complex 94 had the best
behavior within the family of terpy derivatives (IC50(94)¼0.420.1 μM),
whereas the erlotinib derivative, complex 97 was the most cytotoxic within
the Et2bzimpy scaffold (IC50(97)¼6.69 μM). It is worth noting that complexes
92–94 were also tested in leukemia (K562) and gastric carcinoma (SGC7901)
cells delivering very promising IC50 values (IC50¼3.28–8.79 μM). However,
their selectivity toward tumor cells was low as the cytotoxicity value for
HEK293 cells (non-cancerous cells) was also elevated. Additionally, studies
performed by UV–vis absorption spectroscopy, circular dichroism and molec-
ular docking studies showed that complexes 92–94 associate with telomeric
and c-myc G-quadruplexes via groove binding–electrostatic interactions.
Further analysis under crowded conditions (in presence of 40 wt% PEG 200)
revealed that complex 94 is the only one that retained high affinity an
selectivity toward c-myc oncogene.83 Alternatively, complexes 95–97 also
displayed high affinities for G-quadruplex, being those containing a phenyl
acetylene moiety (complexes 96 and 97), the ones that induce a higher degree
of c-myc G-quadruplex stabilization. These data stress the importance of
the structure of the alkynyl ligand within the interaction of Pt(II) and
G-quadruplexes.
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3.4 Dinuclear alkynyl platinum complexes
Dinuclear alkynyl platinum complexes were also investigated as anticancer
agents to widen the spectrum of platinum based drugs. Das and coworkers
reported the first pyrazine based dialkynyl platinum derivatives that have
been tested as anticancer agents.90 Thus, a pyrazine ring was used as a bridge
ligand between two platinum phosphane alkynyl unis at C2 and C6 posi-
tions. Then, each platinum center was covalently linked to an aromatic
or heteroaromatic alkynyl derivative and two triethylphosphane ligands,
affording robust complexes (98–102, see Fig. 11). Analysis of their antip-
roliferative activity against lung cancer A549 cells revealed that only com-
plex 101, bearing a pendant pyridine, had a similar IC50 value to that of
cisplatin (IC50¼3–5 μM). The other diplatinated species showed IC50
values ranging from 10 to 30 μM. Contrary to cisplatin that is able to
undergo hydrolysis in saline water to afford the reactive intermediate aqua
complex, cis-[PtCl(NH3)2(H2O)]
+, with subsequent interaction with the
purine/pyrimidine bases of DNA, complexes 98–102 are robust in those
conditions. Hence, the cytotoxic behavior of these species would be asso-
ciated to a mechanism different of cisplatin, opening the door to additional
biological targets.
3.5 Alkynyl platinum complexes as photosensitizers (PSs)
Alternatively, alkynyl platinum derivatives can be also considered as poten-
tial photosensitizers (PSs) for photodynamic therapy (PDT). In 2014,
Kondaiah and Chakravarty examined for the first time such possibility using
a terpyridine Pt(II) derivative functionalized with a ferrocenyl group to
reduce the undesired toxicity in absence of light.91 It was expected that
the ferrocenyl group would reduce the overall planarity limiting its interca-
lating DNA ability as well as increasing its lipophilicity leading to a higher
biocompatibility. In fact, complex 103 with a propargyl carbazole as
the ancillary ligand showed a very promising behavior as photosensitizer
(Fig. 12). Immortalized human skin keratinocytes (HaCaT cells) and
Fig. 11 Polynuclear platinum alkynyl complexes.
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MCF-7 were treated with 103 in presence and absence of light. In both cell
lines the cytotoxicity of the probe increased up to eight times upon irradi-
ation (IC50(dark)85 μM vs IC50(light)10 μM). The presence of the
alkynyl ligand did not seen decisive for the light-induced toxicity as chloride
analogous (103a) showed similar IC50 values (IC50(dark)70 μM vs
IC50(light)12 μM). In contrast, the photo-activity was mainly attributed
to the ferrocene moiety, which could generate reactive ferrocenenium ion
that effectively activated molecular oxygen.92 Analogous Pt(II) complex lac-
king of the ferrocenyl moiety, complex 103b, did not present a good via-
bility as PS. In particular, complex 103 in presence of light showed a
moderate increment of the sub-G1/G0 population suggesting cell death
leading to fragmented DNA. Annexin V-FITC/PI assay indicated that early
apoptosis was the cell death mechanism mode. This result was further cor-
roborated by electrophoresis performing DNA ladder formation assay. As
expected, external binding to calf thymus DNA was observed instead of
intercalation, driven by the presence of the ferrocenyl moiety. In view of
the promising results with ferrocenylterpyridine platinum alkynyl deriva-
tives, further complexes (104–106, Fig. 12) have been reported for targeted
photo-induced cytotoxicity.93 In this occasion a biotinylated alkynyl was
used as ancillary ligand in order to target specifically cancer cells. Bio-
tinylated derivatives are known to display cancer cell-specific uptake.94,95
In addition, phenylterpyridine analogous were also described, 107–109,
Fig. 12 Photoactive platinum(II) complexes.
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to understand the role of a metal-bound Fc-terpy ligand over Ph-terpy as
photoiniciator. The antiproliferative activity assay in breast carcinoma cells
BT474 and human normal breast epithelial cells HBL-100 revealed that the
biotinylated photoactive Fc-Terpy complexes 104–106 showed consider-
ably higher phoinduced cytotoxicity (IC50(dark)>50 μM vs IC50(light)
12 μM) with a selective uptake by cancer cells, whereas the free ligand
Fc-terpy was inactive in all cases. In contrast, pH-terpy species (107–109)
displayed similar IC50 values in presence and absence of light
(IC50(BT474)15 μM and IC50(HBL-100)27 μM), which revealed
the importance of the ferrocenyl moitety to minimize the undesired toxicity
in absence of light. Additional examination of ROS production by dic-
hlorofluorescein diacetate (DCFH-DA) assay showed that Fc-Terpy deriv-
atives generated ROS within the cells only upon photoexposure to light of
400–700 nm, whereas Ph-Terpy showed ROS generation both in dark and
light conditions. Moreover, annexin V-FICT/PI assay indicated that cell
death was due to an early apoptosis mechanism in all cases and the cell cycle
profiling assay revealed that complexes 104–106 performed a substantial
sub-G1 arrest only upon irradiation. These results contrasted with that
obtained for the species lacking of Fc groups (107–109) as none of them
showed a significant difference between dark and photoexposure condi-
tions, making them inappropriate for photodynamic therapy. Further
DNA binding and cleavage studies emphasized the lack of DNA intercala-
tion for 104–106 which was observed in the case of complexes 107–109
driving by the absence of the Fc unit. Alternatively, complexes 104–106
were found to release the biotinylated ligands in red light (647 nm), which
is believed to photoiniciate a covalent DNA binding by the active platinum
species. Therefore, it could be concluded that the high toxicity attributed to
the Fc-terpy species could be derived from a synergistic cytotoxic effect, the
photorelease of active platinum species and the generation of ROS.
3.6 Dual alkynyl platinum-based photosensitizers
and photoimaging agents
In recent years, Pt(II)-based photosensitizers (PSs) for photodynamic ther-
apy with photoimaging properties have been reported to get insight of the
drug biodistribution in vivo and reveal their possible therapeutic mecha-
nisms. Within this context, near-infrared (NIR) PSs are of particular impor-
tance as this wavelength range is known as the therapeutic window
(700–850 nm), i.e., the light possesses a deeper tissue penetration and it
can reach effectively bigger and inner tumors. Chakravarty and coworkers
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have envisaged a terpyridine alkynyl Pt derivative in which they have incor-
porated a BODIPY derivative (4,4-Difluoro-5,7-dimethyl-4-bora-3a,4a-
diaza-s-indacene) for combining both, the photosensitizing and bioimaging
properties. Additionally, a glucose moiety was introduced in order to
explore the possibility of rendering greater selectivity toward cancer cells,
see compound 110 in Fig. 13.96 BODIPY is well-known for its versatile
photosensitizing and photophysical97 properties and it has been previously
reported to be localized in the mitochondria of cancer cells.98 Additionally,
the use of an appending glucose to look for specific targeting is a common
strategy to confer selectivity as many tumors have the glucose transporter
GLUT-1 overexpressed.99 In the present case, the photoinduced anticancer
activity of 110 and its analogous complex lacking of the appended glucose
moiety, complex 111, as well as the parent complex lacking also of
BODIPY, complex 112, was investigated against HeLa, MCF-7 and
A549 cells in dark and under red light (λ¼600–720 nm). The experiment
showed the crucial role of the BODIPY moiety as complex 112 displayed
IC50 values over 100 μM for the three cell lines in dark and upon radiation.
In contrast, complexes 110 and 111 showed high photocytotoxic activity
with IC50 values ranging from 2.3 to 6.0 μM and from 13.3 to 24.7 μM
under irradiation respectively, and over 91.4 μM in every case in dark con-
ditions. Titration experiments with 1,3-diphenylisobenzofuran (DPBF)
indicated that 110 and 111 generated singlet oxygen (1O2) in red light with
a singlet oxygen quantum yield (ΦΔ) value of ca. 0.6, indicating their pho-
tosensitizing ability. In addition, mass spectroscopy and 1H NMR revealed
that the alkynyl-BODIPY ligand was also released upon red light irradiation.
The fact that complex 110 accomplished better results as PSs agent than 111
suggested its superior capacity to permeate the cells, possibly due to the pres-
ence of the appendant glucose which facilitates its internalization as well as
Fig. 13 Mono- and polynuclear alkynyl platinum complexes.
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enhance the drug aqueous solubility. To further probe this statement, cel-
lular uptake and selectivity studies were performed by flow cytometry using
normal HPL1D and cancer cells (A549). This experiment probed that com-
plex 110 accumulated preferentially in cancer cell than in normal cells and
that its cell permeability was higher than that of 111, emphasizing the role of
the appendant glucose. Finally, fluorescence microscopy demonstrated their
preferential accumulation in the mitochondria over the nucleus, which is a
great input in the development of photodynamic therapy agents.100
4. Conclusions
In conclusion, it is clear that metal alkynyl complexes have many
opportunities to offer in the development of new metal-based chemother-
apeutic agents, especially for gold and platinum derivatives, whose com-
plexes present a great stability due to the MdC^CR bonds. This is a
key feature in drug synthesis because prevents dissociation of the metal spe-
cies in biological media before reaching the target with the consequence
deactivation and toxicity. Many examples of gold derivatives with alkynyl
ligands have been reported, and in most of the cases with the general formula
[Au(C^CR)PR03], and the structure-activity studies have been centered in
changing the substituents in the alkynyl or in the phosphane ligand. In gen-
eral, all the compounds exhibited an excellent cytotoxic activity in different
cancer cell lines but did not show big differences among them to conclude
any structure-activity relationship. Probably, more differences have been
found in the main biological target. Thioredoxin reductase has been rev-
ealed as the main target, for which complexes with strong donating substit-
uents displayed high inhibition efficacy. A cooperative effect was observed
in polynuclear or heteronuclear complexes leading to an increase in the bio-
logical activity compared to their mononuclear precursors was found. Many
gold derivatives with a propargyl-substituted fluorophores have been
described and because of their interesting photophysical properties,
biodistribution studies were performed in order to obtain information about
the cellular uptake and potential biological targets. Alkynyl platinum
complexes with antitumor properties have been described, and they include
different ligand scaffolds such as COD, tridententate N-based or cyclo-
metallated ligands. These compounds, although in general less active than
cisplatin, do not easy dissociate the ligands and, consequently, their cyto-
toxic effect can be associated to a different mechanism to that of cisplatin,
opening the door to additional biological targets. Furthermore, these
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compounds are promising candidates to be used as photosensitizers in
photodynamic therapy with easily tuneable photophysical properties.
Substitution with vectors for specific targeting are encouraging factors for
further development of better and more effective agents in photodynamic
therapy and cell imaging.
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